Aethlon Medical (NASDAQ:AEMD) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a report published on Friday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com started coverage on shares of Aethlon Medical in a research note on Friday, November 8th. They set a “sell” rating on the stock.

Aethlon Medical Trading Down 2.8 %

NASDAQ:AEMD opened at $0.39 on Friday. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.35. The company has a market cap of $5.42 million, a PE ratio of -0.14 and a beta of 1.74. The company has a 50 day simple moving average of $0.40 and a two-hundred day simple moving average of $0.48.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.